{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:03:16Z","timestamp":1794661396874,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_21036"],"award-info":[{"award-number":["MC_PC_21036"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N003284\/1 and MC_UU_00006\/1 and MC_PC_21036"],"award-info":[{"award-number":["MR\/N003284\/1 and MC_UU_00006\/1 and MC_PC_21036"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220044\/Z\/19\/Z"],"award-info":[{"award-number":["220044\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C864\/A14136"],"award-info":[{"award-number":["C864\/A14136"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For many diseases there are delays in diagnosis due to a lack of objective biomarkers for disease onset. Here, in 41,931 individuals from the United Kingdom Biobank Pharma Proteomics Project, we integrated measurements of ~3,000 plasma proteins with clinical information to derive sparse prediction models for the 10-year incidence of 218 common and rare diseases (81\u20136,038 cases). We then compared prediction models developed using proteomic data with models developed using either basic clinical information alone or clinical information combined with data from 37 clinical assays. The predictive performance of sparse models including as few as 5 to 20 proteins was superior to the performance of models developed using basic clinical information for 67 pathologically diverse diseases (median delta C-index\u2009=\u20090.07; range\u2009=\u20090.02\u20130.31). Sparse protein models further outperformed models developed using basic information combined with clinical assay data for 52 diseases, including multiple myeloma, non-Hodgkin lymphoma, motor neuron disease, pulmonary fibrosis and dilated cardiomyopathy. For multiple myeloma, single-cell RNA sequencing from bone marrow in newly diagnosed patients showed that four of the five predictor proteins were expressed specifically in plasma cells, consistent with the strong predictive power of these proteins. External replication of sparse protein models in the EPIC-Norfolk study showed good generalizability for prediction of the six diseases tested. These findings show that sparse plasma protein signatures, including both disease-specific proteins and protein predictors shared across several diseases, offer clinically useful prediction of common and rare diseases.<\/jats:p>","DOI":"10.1038\/s41591-024-03142-z","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:02:25Z","timestamp":1721628145000},"page":"2489-2498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":267,"title":["Proteomic signatures improve risk prediction for common and rare diseases"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3988-7505","authenticated-orcid":false,"given":"Julia","family":"Carrasco-Zanini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3437-9963","authenticated-orcid":false,"given":"Maik","family":"Pietzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Davitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Surendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3466-1846","authenticated-orcid":false,"given":"Damien C.","family":"Croteau-Chonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Torralbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-5395","authenticated-orcid":false,"given":"Christopher","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gr\u00fcnschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-6428","authenticated-orcid":false,"given":"Cai","family":"Ytsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuwa","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Gade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Ziebell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-2051","authenticated-orcid":false,"given":"Simon","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiros","family":"Denaxas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna C.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-2993","authenticated-orcid":false,"given":"Nicholas J.","family":"Wareham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2279-0624","authenticated-orcid":false,"given":"Harry","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3634-3016","authenticated-orcid":false,"given":"Robert A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-7344","authenticated-orcid":false,"given":"Claudia","family":"Langenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"3142_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100353","volume":"16","author":"A Bobrowska","year":"2022","unstructured":"Bobrowska, A. et al. Targeted screening in the UK: a narrow concept with broad application. Lancet Reg. Health Eur. 16, 100353 (2022).","journal-title":"Lancet Reg. Health Eur."},{"key":"3142_CR2","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff Jr.","year":"2014","unstructured":"Goff, D. C. Jr. et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129, S49\u2013S73 (2014).","journal-title":"Circulation"},{"key":"3142_CR3","doi-asserted-by":"publisher","first-page":"e019758","DOI":"10.1136\/bmjopen-2017-019758","volume":"8","author":"C Koshiaris","year":"2018","unstructured":"Koshiaris, C. et al. Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis. BMJ Open 8, e019758 (2018).","journal-title":"BMJ Open"},{"key":"3142_CR4","doi-asserted-by":"publisher","first-page":"e001276","DOI":"10.1136\/bmjresp-2022-001276","volume":"9","author":"N Hoyer","year":"2022","unstructured":"Hoyer, N., Prior, T. S., Bendstrup, E. & Shaker, S. B. Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates. BMJ Open Respir. Res. 9, e001276 (2022).","journal-title":"BMJ Open Respir. Res."},{"key":"3142_CR5","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.3399\/BJGP.2022.0137","volume":"72","author":"M Abo-Tabik","year":"2022","unstructured":"Abo-Tabik, M. et al. Mapping opportunities for the earlier diagnosis of psoriasis in primary care settings in the UK: results from two matched case-control studies. Br. J. Gen. Pract. 72, e834\u2013e841 (2022).","journal-title":"Br. J. Gen. Pract."},{"key":"3142_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(22)00218-6","volume":"21","author":"I Helmrich","year":"2022","unstructured":"Helmrich, I. et al. Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study. Lancet Neurol. 21, 792\u2013802 (2022).","journal-title":"Lancet Neurol."},{"key":"3142_CR7","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41591-019-0665-2","volume":"25","author":"SA Williams","year":"2019","unstructured":"Williams, S. A. et al. Plasma protein patterns as comprehensive indicators of health. Nat. Med. 25, 1851\u20131857 (2019).","journal-title":"Nat. Med."},{"key":"3142_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","volume":"19","author":"A Torkamani","year":"2018","unstructured":"Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of polygenic risk scores. Nat. Rev. Genet. 19, 581\u2013590 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"3142_CR9","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/s41591-021-01549-6","volume":"27","author":"Polygenic Risk Score Task Force of the International Common Disease Alliance.","year":"2021","unstructured":"Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat. Med. 27, 1876\u20131884 (2021).","journal-title":"Nat. Med."},{"key":"3142_CR10","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41591-022-02055-z","volume":"28","author":"J Carrasco-Zanini","year":"2022","unstructured":"Carrasco-Zanini, J. et al. Proteomic signatures for identification of impaired glucose tolerance. Nat. Med. 28, 2293\u20132300 (2022).","journal-title":"Nat. Med."},{"key":"3142_CR11","doi-asserted-by":"publisher","unstructured":"Gadd, D. A. et al. Blood protein levels predict leading incident diseases and mortality in UK Biobank. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.05.01.23288879 (2023).","DOI":"10.1101\/2023.05.01.23288879"},{"key":"3142_CR12","doi-asserted-by":"publisher","first-page":"e008108","DOI":"10.1161\/JAHA.117.008108","volume":"7","author":"JE Ho","year":"2018","unstructured":"Ho, J. E. et al. Protein biomarkers of cardiovascular disease and mortality in the community. J. Am. Heart Assoc. 7, e008108 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"3142_CR13","doi-asserted-by":"publisher","first-page":"eabj9625","DOI":"10.1126\/scitranslmed.abj9625","volume":"14","author":"SA Williams","year":"2022","unstructured":"Williams, S. A. et al. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Sci. Transl. Med. 14, eabj9625 (2022).","journal-title":"Sci. Transl. Med."},{"key":"3142_CR14","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/S2589-7500(19)30012-3","volume":"1","author":"V Kuan","year":"2019","unstructured":"Kuan, V. et al. A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. Lancet Digit. Health 1, e63\u2013e77 (2019).","journal-title":"Lancet Digit. Health"},{"key":"3142_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM197507312930513","volume":"293","author":"TJ Fagan","year":"1975","unstructured":"Fagan, T. J. Letter: Nomogram for Bayes\u2019s theorem. N. Engl. J. Med. 293, 257 (1975).","journal-title":"N. Engl. J. Med."},{"key":"3142_CR16","doi-asserted-by":"publisher","unstructured":"Lutz, R. et al. Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.05.27.542555 (2023).","DOI":"10.1101\/2023.05.27.542555"},{"key":"3142_CR17","unstructured":"Tickle, T. T. I., Georgescu, C., Brown, M. & Haas, B. inferCNV of the Trinity CTAT Project https:\/\/github.com\/broadinstitute\/inferCNV (Klarman Cell Observatory, Broad Institute of MIT and Harvard, 2019)."},{"key":"3142_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.seminhematol.2010.11.003","volume":"48","author":"A Zingone","year":"2011","unstructured":"Zingone, A. & Kuehl, W. M. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol. 48, 4\u201312 (2011).","journal-title":"Semin Hematol."},{"key":"3142_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00505-4","volume":"11","author":"A Visram","year":"2021","unstructured":"Visram, A. et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 11, 120 (2021).","journal-title":"Blood Cancer J."},{"key":"3142_CR20","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2016.5951","volume":"315","author":"P Ganz","year":"2016","unstructured":"Ganz, P. et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA 315, 2532\u20132541 (2016).","journal-title":"JAMA"},{"key":"3142_CR21","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","volume":"388","author":"PF Pinsky","year":"2023","unstructured":"Pinsky, P. F. & Parnes, H. Screening for prostate cancer. N. Engl. J. Med. 388, 1405\u20131414 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3142_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43575-7","volume":"14","author":"J You","year":"2023","unstructured":"You, J. et al. Plasma proteomic profiles predict individual future health risk. Nat. Commun. 14, 7817 (2023).","journal-title":"Nat. Commun."},{"key":"3142_CR23","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","volume":"127","author":"YT Tai","year":"2016","unstructured":"Tai, Y. T. et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood 127, 3225\u20133236 (2016).","journal-title":"Blood"},{"key":"3142_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/cbf.3169","volume":"34","author":"X Shen","year":"2016","unstructured":"Shen, X. et al. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways. Cell Biochem. Funct. 34, 104\u2013110 (2016).","journal-title":"Cell Biochem. Funct."},{"key":"3142_CR25","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Usmani, S. Z. & Yong, K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 8, e446\u2013e461 (2021).","journal-title":"Lancet Haematol."},{"key":"3142_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3142_CR27","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3142_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. & Kochenderfer, J. N. CAR T cell therapies for patients with multiple myeloma. Nat. Rev. Clin. Oncol. 18, 71\u201384 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3142_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.20517\/cdr.2022.138","volume":"6","author":"V Sammartano","year":"2023","unstructured":"Sammartano, V. et al. Anti-BCMA novel therapies for multiple myeloma. Cancer Drug Resist. 6, 169\u2013181 (2023).","journal-title":"Cancer Drug Resist."},{"key":"3142_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","volume":"4","author":"AL Garfall","year":"2023","unstructured":"Garfall, A. L. et al. Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 4, 118\u2013133 (2023).","journal-title":"Blood Cancer Discov."},{"key":"3142_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","volume":"19","author":"A Guenther","year":"2018","unstructured":"Guenther, A. et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir. Res 19, 141 (2018).","journal-title":"Respir. Res"},{"key":"3142_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","volume":"20","author":"TM Maher","year":"2019","unstructured":"Maher, T. M. & Strek, M. E. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir. Res 20, 205 (2019).","journal-title":"Respir. Res"},{"key":"3142_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/ejhf.255","volume":"17","author":"M Harakalova","year":"2015","unstructured":"Harakalova, M. et al. A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle-specific genes. Eur. J. Heart Fail 17, 484\u2013493 (2015).","journal-title":"Eur. J. Heart Fail"},{"key":"3142_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1517\/21678707.2015.1057498","volume":"3","author":"M Sweet","year":"2015","unstructured":"Sweet, M., Taylor, M. R. & Mestroni, L. Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. Expert Opin. Orphan Drugs 3, 869\u2013876 (2015).","journal-title":"Expert Opin. Orphan Drugs"},{"key":"3142_CR35","first-page":"zqab062","volume":"3","author":"S Duan","year":"2022","unstructured":"Duan, S., Rico, K. & Merchant, J. L. Gastrin: from physiology to gastrointestinal malignancies. Funct. (Oxf.) 3, zqab062 (2022).","journal-title":"Funct. (Oxf.)"},{"key":"3142_CR36","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s41591-022-01980-3","volume":"28","author":"T Buergel","year":"2022","unstructured":"Buergel, T. et al. Metabolomic profiles predict individual multidisease outcomes. Nat. Med. 28, 2309\u20132320 (2022).","journal-title":"Nat. Med."},{"key":"3142_CR37","doi-asserted-by":"publisher","unstructured":"Thompson, D. J. et al. UK Biobank release and systematic evaluation of optimised polygenic risk scores for 53 diseases and quantitative traits. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2022.06.16.22276246 (2022).","DOI":"10.1101\/2022.06.16.22276246"},{"key":"3142_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","volume":"2","author":"PE Geyer","year":"2016","unstructured":"Geyer, P. E. et al. Plasma proteome profiling to assess human health and disease. Cell Syst. 2, 185\u2013195 (2016).","journal-title":"Cell Syst."},{"key":"3142_CR39","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","volume":"186","author":"A Fry","year":"2017","unstructured":"Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026\u20131034 (2017).","journal-title":"Am. J. Epidemiol."},{"key":"3142_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature 622, 329\u2013338 (2023).","journal-title":"Nature"},{"key":"3142_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41588-020-00757-z","volume":"53","author":"N Sinnott-Armstrong","year":"2021","unstructured":"Sinnott-Armstrong, N. et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat. Genet. 53, 185\u2013194 (2021).","journal-title":"Nat. Genet."},{"key":"3142_CR42","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.cell.2020.08.008","volume":"182","author":"D Vuckovic","year":"2020","unstructured":"Vuckovic, D. et al. The polygenic and monogenic basis of blood traits and diseases. Cell 182, 1214\u20131231 e1211 (2020).","journal-title":"Cell"},{"key":"3142_CR43","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.mcpro.2021.100168","volume":"20","author":"L Wik","year":"2021","unstructured":"Wik, L. et al. Proximity extension assay in combination with next-generation sequencing for high-throughput proteome-wide analysis. Mol. Cell Proteom. 20, 100168 (2021).","journal-title":"Mol. Cell Proteom."},{"key":"3142_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22767-z","volume":"12","author":"W Zhong","year":"2021","unstructured":"Zhong, W. et al. Next generation plasma proteome profiling to monitor health and disease. Nat. Commun. 12, 2493 (2021).","journal-title":"Nat. Commun."},{"key":"3142_CR45","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven, D. J. & Buhlmann, P. MissForest\u2014non-parametric missing value imputation for mixed-type data. Bioinformatics 28, 112\u2013118 (2012).","journal-title":"Bioinformatics"},{"key":"3142_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.32614\/RJ-2014-008","volume":"6","author":"N Lunardon","year":"2014","unstructured":"Lunardon, N., Menardi, G. & Torelli, N. ROSE: a package for binary imbalanced learning. R. J. 6, 78\u201379 (2014).","journal-title":"R. J."},{"key":"3142_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12859-016-1323-z","volume":"17","author":"GE Hoffman","year":"2016","unstructured":"Hoffman, G. E. & Schadt, E. E. variancePartition: interpreting drivers of variation in complex gene expression studies. BMC Bioinf. 17, 483 (2016).","journal-title":"BMC Bioinf."},{"key":"3142_CR48","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser, A., Steiner, C., Harris, D. R. & Coffey, R. M. Comorbidity measures for use with administrative data. Med. Care 36, 8\u201327 (1998).","journal-title":"Med. Care"},{"key":"3142_CR49","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"3142_CR50","doi-asserted-by":"publisher","first-page":"ELIXIR-709","DOI":"10.12688\/f1000research.24956.2","volume":"9","author":"L Kolberg","year":"2020","unstructured":"Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2\u2013an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res 9, ELIXIR-709 (2020).","journal-title":"F1000Res"},{"key":"3142_CR51","first-page":"95","volume":"80","author":"N Day","year":"1999","unstructured":"Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. Br. J. Cancer 80, 95\u2013103 (1999).","journal-title":"Br. J. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03142-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03142-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03142-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T08:25:14Z","timestamp":1726647914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03142-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["3142"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03142-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D., P.S., D.C.C.-C., C.R., T.K., S.G., D.F., F.Z., J.B. and R.A.S. are all employees of and\/or shareholders of GSK. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}